Cannabinoid receptors and pain

Progress in Neurobiology

Volumn 63, Issue 5, 2001, Pages 569-611

  Pertwee, Roger G ^a  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; 5 (4 CHLORO 3 METHYLPHENYL) 1 (4 METHYLBENZYL) N (1,3,3 TRIMETHYLBICYCLO[2.2.1]HEPTAN 2 YL) 3 PYRAZOLECARBOXAMIDE; ANANDAMIDE; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CANNABINOID RECEPTOR; CANNABINOID RECEPTOR AGONIST; CANNABINOID RECEPTOR ANTAGONIST; DRONABINOL; GUANINE NUCLEOTIDE BINDING PROTEIN; RIMONABANT;

ANTINOCICEPTION; ARTICLE; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; GENE EXPRESSION; GENE LOCATION; MOUSE; NONHUMAN; PAIN; PRIORITY JOURNAL; RAT;

EID: 0035150352     PISSN: 03010082     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0301-0082(00)00031-9     Document Type: Review

References (250)

1. (R)-methanandamide: A chiral novel anandamide possessing higher potency and metabolic stability
2. Evaluation of cannabinoid receptor binding and in vivo activities for anandamide analogs
3. Assessment of anandamide interaction with the cannabinoid brain receptor: SR 141716A antagonism studies in mice and autoradiographic analysis of receptor binding in rat brain
4. Cannabinomimetic behavioral effects of and adenylate cyclase inhibition by two new endogenous anandamides
5. 9-tetrahydrocannabinol in the mouse
6. Role of prostaglandins in some neuropharmacological actions of delta-9-tetrahydrocannabinol (THC) in the rat
7. Pharmacological effects of two active constituents of marijuana
8. 9-tetrahydrocannabinol in the mouse
9. A selective inverse agonist for central cannabinoid receptor inhibits mitogen-activated protein kinase activation stimulated by insulin or insulin-like growth factor 1. Evidence for a new model of receptor/ligand interactions
10. Cannabinoid signalling in cultured rat cerebellar granule cells
11. 9-tetrahydrocannabinol on spasticity: A pilot study with two patients
12. The cannabinoid acids: Nonpsychoactive derivatives with therapeutic potential
13. Cannabinoids and pain response: A possible role for prostaglandins
14. Antagonism to the actions of platelet activating factor by a nonpsychoactive cannabinoid
15. Synthetic nonpsychotropic cannabinoids with potent antiinflammatory, analgesic, and leukocyte antiadhesion activities
16. 8-THC-11-oic acid (CT3) in mice
17. 9-tetrahydrocannabinol in the rat and mouse
18. Influence of cannabinoids on electrically evoked dopamine release and cyclic AMP generation in the rat striatum
19. 1 receptor
20. Control of pain initiation by endogenous cannabinoids
21. 9-tetrahydrocannabinol-induced antinociception in rats
22. Presynaptic inhibition of GABAergic inputs to rat substantia nigra pars reticulata neurones by a cannabinoid agonist
23. Occlusion of the presynaptic action of cannabinoids in rat substantia nigra pars reticulata by cadmium
24. 1 receptor antagonist, SR141716A, selectively facilitates nociceptive responses of dorsal horn neurones in the rat
25. 9-tetrahydrocannabinol: Dose-response analysis and receptor identification
26. 8-tetrahydrocannabinol
27. 9-tetrahydrocannabinol
28. Pharmacological profile of a series of bicyclic cannabinoid analogs: Classification as cannabimimetic agents
29. Cannabinoid structure-activity relationships: Correlation of receptor binding and in vivo activities
30. 9-tetrahydrocannabinol-induced responses and apparent agonist activity
31. The effect of the enzyme inhibitor phenylmethylsulfonyl fluoride on the pharmacological effect on anandamide in the mouse model of cannabimimetic activity
32. The perceived effects of smoked cannabis on patients with multiple sclerosis
33. 9-tetrahydrocannabinol increases prodynorphin and proenkephalin gene expression in the spinal cord of the rat
34. 1 receptor agonists
35. Comparison of novel cannabinoid partial agonists and SR141716A in the guinea-pig small intestine
36. Inhibition by cannabinoid receptor agonists of acetylcholine release from the guinea-pig myenteric plexus
37. Antinociceptive activity of menabitan
38. 9-tetrahydrocannabinol
39. Cannabinoid pharmacology
40. Pharmacology of some marijuana constituents and two heterocyclic analogues
41. 9-tetrahydrocannabinol in laboratory rodents
42. Interactions between synthetic vanilloids and the endogenous cannabinoid system
43. Endocannabinoids: Endogenous cannabinoid receptor ligands with neuromodulatory action
44. 6-THC-7-oic acid
45. Synthesis, pharmacology, and molecular modeling of novel 4-alkyloxy indole derivatives related to cannabimimetic aminoalkyl indoles (AAIs)
46. Antisense oligodeoxynucleotide treatment to the brain cannabinoid receptor inhibits antinociception
47. Mast cells express a peripheral cannabinoid receptor with differential sensitivity to anandamide and palmitoylethanolamide
48. Marinol and phantom limb pain: A case study
49. Analgesic and antiinflammatory activity of constituents of Cannabis sativa L.
50. Pharmacological activity of the cannabinoid receptor agonist, anandamide, a brain constituent
51. Identification of genes differentially expressed by nerve growth factor- and neurotrophin-3-dependent sensory neurons
52. Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations
53. 9-tetrahydrocannabinol
54. 2+ channel current
55. Cannabis-induced potentiation of morphine analgesia in rat-role of brain monoamines
56. Electrically evoked acetylcholine release from hippocampal slices is inhibited by the cannabinoid receptor agonist, WIN 55212-2, and is potentiated by the cannabinoid antagonist, SR 141716A
57. Examination of the effect of the cannabinoid receptor agonist, CP 55,940, on electrically evoked transmitter release from rat brain slices
58. Effect of the cannabinoid receptor SPECT agent, AM 281, on hippocampal acetylcholine release from rat brain slices
59. Potentiation of the action of anandamide on hippocampal slices by the fatty acid amide hydrolase inhibitor, palmitylsulphonyl fluoride (AM 374)
60. A comparison of THC, nantradol, nabilone, and morphine in the chronic spinal dog
61. Cannabinoid receptors in the human brain: A detailed anatomical and quantitative autoradiographic study in the fetal, neonatal and adult human brain
62. 1 receptor
63. 2, a peripheral cannabinoid receptor
64. Pharmacology of pravadoline: A new analgesic agent
65. Characterization and localization of cannabinoid receptors in rat brain: A quantitative in vitro autoradiographic study
66. The analgesic effects of R(+)-WIN 55,212-2 mesylate, a high affinity cannabinoid agonist, in a rat model of neuropathic pain
67. 1 cannabinoid receptor activation on cerebellar granule cell nitric oxide synthase activity
68. 9-tetrahydrocannabinol: Two-way cross tolerance for antinociceptive and heart-rate responses in the rat
69. + channels
70. Regulation of cannabinoid and μ-opioid receptors in rat lumbar spinal cord following neonatal capsaicin treatment
71. 1 receptor messenger RNA in neuronal subpopulations of rat dorsal root ganglia: A double-label in situ hybridization study
72. Cannabinoid receptors undergo axonal flow in sensory nerves
73. Cannabinoid modulation of wide dynamic range neurons in the lumbar dorsal horn of the rat by spinally administered WIN55,212-2
74. Pre- and postsynaptic distribution of cannabinoid and μ-opioid receptors in rat spinal cord
75. Intrathecal cannabinoid administration suppresses noxious stimulus-evoked Fos protein-like immunoreactivity in rat spinal cord: Comparison with morphine
76. Cannabinoid suppression of noxious heat-evoked activity in wide dynamic range neurons in the lumbar dorsal horn of the rat
77. Pain relief with oral cannabinoids in familial Mediterranean fever
78. Liquid chromatographic-mass spectrometric measurement of the endogenous cannabinoid 2-arachidonylglycerol in the spinal cord and peripheral nervous system
79. Cannabimimetic indoles, pyrroles and indenes
80. Recent developments in the medicinal chemistry of cannabinoids
81. 2 receptor
82. 1 receptors on peripheral sympathetic nerves
83. 9-tetrahydrocannabinol on intestinal motility and on the abdominal constriction response in the mouse
84. 2 receptor agonist palmitoylethanolamide in visceral and somatic inflammatory pain
85. 2 ligand palmitoylethanolamide, prevents the viscero-visceral hyperreflexia associated with inflammation of the rat urinary bladder
86. Evaluation of intramuscular levonantradol and placebo in acute postoperative pain
87. The discovery of nonclassical cannabinoid analgetics
88. 1 receptor-mediated inhibition of NMDA- and kainate-stimulated noradrenaline and dopamine release in the brain
89. 1 receptors
90. 1 cannabinoid receptors regulate GABA release from axon terminals of specific hippocampal interneurons
91. 9-tetrahydrocannabinol (THC)
92. 9-tetrahydrocannabinol in the dog
93. 1 and the induction of GDP/GTP exchange
94. A model for the study of cannabinoid actions in microglia
95. 1 cannabinoid receptors inhibits neurotransmitter release from identified synaptic sites in rat hippocampal cultures
96. 9-tetrahydrocannabinol attenuates capsaicin-induced thermal nociception in rhesus monkeys: A peripheral cannabinoid action
97. 3H]flunitrazepam binding and analgesic activity of synthetic cannabimimetics
98. 9-tetrahydrocannabinol in the rat
99. Morpholinoalkylindenes as antinociceptive agents: Novel cannabinoid receptor agonists
100. The palmitoylethanolamide and oleamide enigmas: Are these two fatty acid amides cannabimimetic?
101. 2 cannabinoid, as potential ligands for the cannabinoid receptors
102. 1 receptor knockout mice
103. Cannabinoids decrease excitatory synaptic transmission and impair long-term depression in rat cerebellar Purkinje cells
104. The cannabinoid receptor agonist WIN 55,212-2 mesylate blocks the development of hyperalgesia produced by capsaicin in rats
105. 2-noradrenergic mechanism
106. Spinal and supraspinal components of cannabinoid-induced antinociception
107. The selective cannabinoid antagonist SR 141716A blocks cannabinoid-induced antinociception in rats
108. The antinociceptive effects of intrathecally administered cannabinoids are influenced by lipophilicity
109. Evidence that the antinociceptive tail-flick response is produced independently from changes in either tail-skin temperature or core temperature
110. Investigation of brain sites mediating cannabinoid-induced antinociception in rats: Evidence supporting periaqueductal gray involvement
111. Pharmacology and stereoselectivity of structurally novel cannabinoids in mice
112. 8-THC-dimethylheptyl in mice and dogs
113. Distribution of neuronal cannabinoid receptor in the adult rat brain: A comparative receptor binding radioautography and in situ hybridization histochemistry
114. Chronic administration of cannabinoids regulates proenkephalin mRNA levels in selected regions of the rat brain
115. Two distinctive antinociceptive systems in rats with pathological pain
116. Characterization of the antinociceptive activity of intravenously administered delta-9-tetrahydrocannabinol in mice
117. Structural requirements for cannabinoid-induced antinoceptive activity in mice
118. Behavioral, biochemical, and molecular modeling evaluations of cannabinoid analogs
119. 9-THC
120. Antinociceptive actions of cannabinoids following intraventricular administration in rats
121. 9-THC: Reassessment of the putative three-point cannabinoid-receptor interaction
122. Structural requirements for cannabinoid receptor probes
123. Suppression of noxious stimulus-evoked activity in the ventral posterolateral nucleus of the thalamus by a cannabinoid agonist: Correlation between electrophysiological and antinociceptive effects
124. Cannabinoid receptor-mediated inhibition of the rat tail-flick reflex after microinjection into the rostral ventromedial medulla
125. Manipulation of the tetrahydrocannabinol side chain delineates agonists, partial agonists, and antagonists
126. Discovery and characterization of endogenous cannabinoids
127. Anatomical basis for cannabinoid-induced antinociception as revealed by intracerebral microinjections
128. Spinal cannabinoids are anti-allodynic in rats with persistent inflammation
129. Nabilone in the treatment of multiple sclerosis
130. Cannabinoid modulation of dynorphin A: Correlation to cannabinoid-induced antinociception
131. Delta-9-tetrahydrocannabinol shows antispastic and analgesic effects in a single case double-blind trial
132. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors
133. Endocannabinoids
134. A cannabinoid derived prototypical analgesic
135. Structure-activity relationships for cannabinoid receptor-binding and analgesic activity: Studies of bicyclic cannabinoid analogs
136. An analgesia circuit activated by cannabinoids
137. Presynaptic cannabinoid and imidazoline receptors in the human heart and their potential relationship
138. The endogenous cannabinoid anandamide potentiates interleukin-6 production by astrocytes infected with Theiler's murine encephalomyelitis virus by a receptor-mediated pathway
139. Effects of cannabinoids on the immune system and central nervous system: Therapeutic implications
140. 9-tetrahydrocannabinol as measured with the formalin test
141. Cannabinoid receptors differentially modulate potassium A and D currents in hippocampal neurons in culture
142. Molecular characterization of a peripheral receptor for cannabinoids
143. 1 receptors
144. 2+ signals in cerebellar granule neurons in culture
145. Analgesic interaction between nitrous oxide and delta-9-tetrahydrocannabinol in the rat
146. The analgesic properties of delta-9-tetrahydrocannabinol and codeine
147. Analgesic effect of delta-9-tetrahydrocannabinol
148. 1 cannabinoid receptor in primate brain
149. 1 cannabinoid receptor in the primate spinal cord
150. 9-tetrahydrocannabinol and some synthetic analogues
151. 1 cannabinoid receptor activity
152. 9-THC
153. The pharmacology of cannabis in animals
154. Tolerance to and dependence on psychotropic cannabinoids
155. 2 receptors
156. Advances in cannabinoid receptor pharmacology
157. Pharmacology of cannabinoid receptor ligands
158. Prescribing cannabinoids for multiple sclerosis - Current issues
159. An investigation of the involvement of GABA in certain pharmacological effects of delta-9-tetrahydrocannabinol
160. 1 receptors in guinea-pig small intestine
161. O-1057, a potent water-soluble cannabinoid receptor agonist with antinociceptive properties
162. Structural determinants for recognition and translocation by the anandamide transporter
163. 9-THC in the spinal cord
164. 9-tetrahydrocannabinol and morphine in the spinal cord
165. Involvement of dynorphin B in the antinociceptive effects of the cannabinoid CP55,940 in the spinal cord
166. 9-THC, WIN 55,212-2 and anandamide in mice
167. 9-tetrahydrocannabinol-induced analgesia in mice
168. 9-tetrahydrocannabinol-induced analgesia by morphine in mice: Involvement of μ- and κ-opioid receptors
169. 9-tetrahydrocannabinol-induced antinociception in mice
170. Investigation of the role of the phenolic hydroxyl in cannabinoid activity
171. A rational search for the separation of psychoactivity and analgesia in cannabinoids
172. 8-tetrahydrocannabinol analogs
173. Cannabinol derivatives: Binding to cannabinoid receptors and inhibition of adenylylcyclase
174. SR 141716A, a cannabinoid receptor antagonist, produces hyperalgesia in untreated mice
175. Hypoactivity of the spinal cannabinoid system results in NMDA-dependent hyperalgesia
176. Antihyperalgesic effects of spinal cannabinoids
177. 1 receptors
178. SR141716A, a potent and selective antagonist of the brain cannabinoid receptor
179. 2+ currents in neonatal rat cultured DRG neurones
180. 9-THC-induced antinociceptive tolerance
181. Potent anandamide analogs: The effect of changing the length and branching of the end pentyl chain
182. Interactions among the cannabinoids in the antagonism of the abdominal constriction response in the mouse
183. 1 receptor localization in rat spinal cord and roots, dorsal root ganglion, and peripheral nerve
184. Behavioral effects in monkeys of racemates of two biologically active marijuana constituents
185. Cannabinoid receptor-mediated inhibition of dopamine release in the retina
186. 1 receptor-mediated inhibition of noradrenaline release in the human and guinea-pig hippocampus
187. + M-current in hippocampal CA1 neurons
188. Cannabis sativa L. (Marijuana) V: Pharmacological evaluation of marijuana aqueous extract and volatile oil
189. Structure and receptor activity for classical cannabinoids
190. Synthesis and pharmacological comparison of dimethylheptyl and pentyl analogs of anandamide
191. Cannabinoid receptor agonists inhibit glutamatergic synaptic transmission in rat hippocampal cultures
192. The cannabinoid agonist WIN55,212-2 inhibits calcium channels by receptor-mediated and direct pathways in cultured rat hippocampal neurons
193. Cannabinoid receptor agonists protect cultured rat hippocampal neurons from excitotoxicity
194. 9-Tetrahydrocannabinol acts as a partial agonist to modulate glutamatergic synaptic transmission between rat hippocampal neurons in culture
195. Psychoactive cannabinoids reduce gastrointestinal propulsion and motility in rodents
196. 2): Identification of cannabinoid receptor subtype selective ligands
197. 9-tetrahydrocannabinols
198. 8-tetrahydrocannabinol
199. The ALIAmide palmitoylethanolamide and cannabinoids, but not anandamide, are protective in a delayed postglutamate paradigm of excitotoxic death in cerebellar granule neurons
200. The endogenous lipid anandamide is a full agonist at the human vanilloid receptor (hVR1)
201. 9-tetrahydrocannabinol-induced analgesia
202. The pharmacological activity of anandamide, a putative endogenous cannabinoid, in mice
203. 9-tetrahydrocannabinol and kappa opioids in mice
204. 9-tetrahydrocannabinol
205. 9-tetrahydrocannabinol and anandamide antinociception in non-arthritic and arthritic rats
206. 9-tetrahydrocannabinol in mice and rats
207. 9-tetrahydrocannabinol (THC)
208. Comparative analgesic activity of various naturally occurring cannabinoids in mice and rats
209. 9-THC
210. Effects of delta-9-tetrahydrocannabinol on halothane MAC in dogs
211. 1 receptors and ligands in vertebrate retina: Localization and function of an endogenous signaling system
212. Evidence for a role of endogenous cannabinoids in the modulation of acute and tonic pain sensitivity
213. Cannabinoid WIN 55,212-2 inhibits the activity-dependent facilitation of spinal nociceptive responses
214. Mechanisms of cannabinoid-receptor-mediated inhibition of synaptic transmission in cultured hippocampal pyramidal neurons
215. Inhibition of GABAergic inhibitory postsynaptic currents by cannabinoids in rat corpus striatum
216. 9-tetrahydrocannabinol
217. 2 and receptor differentiation: A statistical analysis of competitive antagonism
218. Modeling the cannabinoid receptor: A three-dimensional quantitative structure-activity analysis
219. 9-THC-DMH
220. 9-tetrahydrocannabinol in mice
221. 9-tetrahydrocannabinol in mice
222. Suppression of noxious stimulus-evoked expression of Fos protein-like immunoreactivity in rat spinal cord by a selective cannabinoid agonist
223. 1 receptors in the rat central nervous system
224. 9-tetrahydrocannabinol in rats
225. Cannabinoid receptor activation inhibits GABAergic neurotransmission in rostral ventromedial medulla neurons in vitro
226. Actions of cannabinoids on membrane properties and synaptic transmission in rat periaqueductal gray neurons in vitro
227. Effects of delta-9-tetrahydrocannabinol on cyclopropane MAC in the rat
228. Analgesic, respiratory and heart rate effects of cannabinoid and opioid agonists in rhesus monkeys: Antagonist effects of SR 141716A
229. Mesenteric vasodilation mediated by endothelial anandamide receptors
230. 1) mediates inhibition of nitric oxide production by rat microglial cells
231. Pain modulation by release of the endogenous cannabinoid anandamide
232. Comparison of pharmacological effects of tetrahydrocannabinols and their 11-hydroxy-metabolites in mice
233. Cannabimimetic activity from CP-47,497, a derivative of 3-phenylcyclohexanol
234. Effect of cannabinoids on the abdominal constriction response in mice: Within cannabinoid interactions
235. Blockade of cannabinoid-induced antinociception by norbinaltorphimine, but not N,N-diallyl-tyrosine-Aib-phenylalanine-leucine, ICI 174,864 or naloxone in mice
236. Blockade of cannabinoid-induced antinociception by naloxone benzoylhydrazone (NalBZH)
237. 9-THC-induced interactions with dynorphinergic systems
238. Synergistic interactions of endogenous opioids and cannabinoid systems
239. Antinociceptive activity of intrathecally administered cannabinoids alone, and in combination with morphine, in mice
240. 9-THC-induced antinociception
241. Modulation of cannabinoid-induced antinociception after intracerebroventricular versus intrathecal administration to mice: Possible mechanisms for interaction with morphine
242. Differential blockade of the antinociceptive effects of centrally administered cannabinoids by SR141716A
243. Structure-activity relationships of indole- and pyrrole-derived cannabinoids
244. 8-tetrahydrocannabinol
245. Analgesic properties of the tetrahydrocannabinols, their metabolites and analogs
246. The antinociceptive effects of intrathecally administered levonantradol and desacetyllevonantradol in the rat
247. Synthesis and pharmacological properties of 11-hydroxy-3-(1′,1′-dimethylheptyl)hexahydrocannabinol: A high-affinity cannabinoid agonist
248. 1 receptor knockout mice
249. Dimethylheptyl-THC-11 oic acid. A nonpsychoactive antiinflammatory agent with a cannabinoid template structure
250. Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide